Navigation Links
ForteBio Announces Launch of Protein G Biosensor for Use on Company's Octet® Instruments
Date:9/3/2010

MENLO PARK, Calif., Sept. 3 /PRNewswire/ -- ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution. Because it runs on the company's label-free Octet instrumentation platform, the new biosensor enables such measurements with unprecedented speed, ease of use and cost-efficiency. The company also announced that it has completed International Standards Organization (ISO) certification of its biosensor manufacturing facility.

"Protein G uniquely binds to many mammalian IgGs, such as murine, goat, bovine and other IgGs, making it an important tool in antibody discovery, cell line development and production monitoring," said Christopher Silva, ForteBio's vice president of marketing. "Traditional IgG quantification methods for numerous species and subtypes using Protein G, however, are complicated, labor-intensive and time-consuming. Now, with ForteBio's new Protein G biosensor, researchers can obtain highly specific binding information in real time, in a cost-effective and easy-to-use manner." Mr. Silva also noted that the company's Protein G biosensor can be regenerated and reused, for increased workflow flexibility and cost-efficiency.

The new biosensor comes with recombinant Protein G pre-immobilized on the surface and is ready to use on ForteBio's Octet instruments. ForteBio's Octet platform is based on the company's proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify kinetic characterization and quantitation by eliminating throughput and time-to-result limitations of traditional SPR-based assays and ELISA. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

To date over 2.5 million biosensor assays have been run on Octet systems, a testament to the high reproducibility, accuracy and robustness of the platform.

The company also announced that its biosensor manufacturing facility is now ISO 9001:2008-certified, underscoring the quality of its products.

ABOUT FORTEBIO, INC.ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com. Contact: Gemma Milan650-289-6800gmilan@fortebio.com
'/>"/>

SOURCE ForteBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
2. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
3. Nutraceutical Leader Announces Internal Promotions of Key Personnel
4. United American Healthcare Corporation Announces Increase in Board Size and New Director Nominees
5. Ellman International Announces Executive Team Hire
6. Yongye International Announces RMB 400 Million Revolving Credit Facilities
7. QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR
8. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
9. Golden Meditech Announces Plan to Issue Taiwan Depository Receipts
10. Accuray Announces Results for Fourth Quarter and Fiscal Year 2010
11. Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 Amgen (NASDAQ: AMGN ) will present ... Conference at 9:15 a.m. ET on Wednesday, Feb. 10, 2016, ... W. Meline , executive vice president and chief financial officer ... the presentation can be accessed from the Events Calendar on ... the webcast will also be available on Amgen,s website for ...
(Date:2/5/2016)... 2016  Patients in Alabama seeking ... therapy no longer have to travel out of state. ... Urology Centers of Alabama to provide a total ... qualifying patients. Alabama is ... of prostate cancer using many different modalities. They are the ...
(Date:2/5/2016)... York , February 5, 2016 ... Transparency Market Research report states that the global active ... 2014 and is predicted to reach US$185.9 bn by ... of 6.50% from 2014 to 2020. The title of ... Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic Area) ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 2016 , ... US Sports Camps , official operators of Nike Yoga ... kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New England ... Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering ...
(Date:2/5/2016)... ... 2016 , ... The American public tends to feel uncomfortable about drinking recycled ... municipal or well water. The recent experience with lead contaminated water in Flint, Michigan, ... way toward increasing public acceptance of recycled waste water as drinking water. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today announced that ... donate to Give To Cure’s campaign that is crowdfunding clinical trials to help find ... share payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in ...
(Date:2/5/2016)... ... 2016 , ... Pivot Point Consulting, a leading national Healthcare ... Services for HIT Implementation Support & Staffing report with an outstanding score of ... healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. , ...
(Date:2/5/2016)... ... , ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental ... individuals in need. The event is scheduled to take place on February 27, 2016 ... provide dental care to community members in need. Each patient will be given the ...
Breaking Medicine News(10 mins):